What role do telomeres play in age-related changes in the organism? A preclinical study published in 2011 in the scientific journal Aging Cell investigated the telomerase activator TA-65® in cell cultures and in adult and aged mice.
The study focused on telomerase activity, changes in particularly short telomeres, and various age-related health markers. These included, among others, glucose metabolism, bone health, and certain skin parameters.
Important: The results originate from cell and animal experiments. They provide clues about biological mechanisms but are not proof of comparable effects in humans.
Fundamental information about the chromosome structures studied can be found in our technical article Telomeres and Telomerase.
What was examined in the study?
The research group led by Bruno Bernardes de Jesus and Maria A. Blasco investigated the effect of TA-65® on various biological processes associated with telomere biology and aging.
The investigations were carried out in two areas:
- Cell culture experiments: Analysis of telomerase activity, telomere length, and specific markers for DNA damage in mouse cells.
- Animal experiments: Examination of adult and aged mice that received TA-65® through their diet.
Various biological metrics were examined in the mice, including:
- Telomerase activity in selected tissues.
- Changes in telomere length distribution.
- Glucose tolerance and metabolic parameters.
- Bone-related metrics.
- Specific changes in skin and subcutaneous tissue.
- The occurrence of tumors during the study.
What results did the cell culture experiments show?
The researchers examined, among other things, embryonic fibroblasts from mice whose telomere maintenance was genetically impaired.
Under specific experimental conditions, treatment with TA-65® led to increased telomerase activity.
In cells with existing telomerase function, changes in telomere length and a lower proportion of particularly short telomeres were also observed.
At the same time, certain markers for DNA damage decreased.
In contrast, these effects were not observed in a comparable manner in cells lacking a necessary component of telomerase.
These results suggest that the observed changes under the conditions studied were related to telomerase function.
What changes were observed in the mice?
In the animal experiments, adult and aged mice received TA-65® as part of their diet.
The scientists subsequently examined various cellular and age-related parameters.
Telomerase activity and short telomeres
In certain tissues of treated mice, changes in the expression of telomerase components were detected.
Furthermore, the researchers observed a lower proportion of particularly short telomeres in selected investigations.
The results suggest that TA-65® was able to influence certain telomere maintenance processes under the conditions of the mouse model.
Glucose metabolism
The researchers also investigated the animals' glucose metabolism.
In certain treated mouse groups, more favorable results were observed in glucose tolerance tests and other metabolic measurements.
These results relate exclusively to the animals and experimental conditions studied.
Bone-related metrics
The study reported on changes in specific bone tissue parameters in treated mice.
In doing so, the scientists investigated age-related changes that are, among other things, associated with osteoporosis.
However, it cannot be inferred from these animal data that TA-65® prevents or treats osteoporosis in humans.
Skin parameters
Changes in certain age-related skin and subcutaneous parameters were also documented in the examined mouse groups.
These observations are of interest for experimental aging research.
However, they are not clinical evidence that TA-65® reduces skin aging or UV-induced skin damage in humans.
What did the study show regarding cancer risk?
Since telomerase also plays an important role in many cancer cells, the occurrence of tumors was investigated as part of the animal experiments.
The authors reported that no statistically significant increase in overall cancer incidence was detected in the treated mice during the study.
However, this result must be interpreted with caution.
The absence of a statistically significant difference does not mean that a potential risk can be fundamentally excluded.
In particular, the limited duration and conditions of the animal experiments do not allow for a reliable statement regarding the long-term safety of intake in humans.
What do the results mean for longevity research?
The study provides preclinical evidence of potential links between telomerase activity, telomere maintenance, and various age-related biological metrics.
In longevity research, scientists investigate which mechanisms are associated with healthy aging and the maintenance of physical functions.
An important term in this context is healthspan. It describes the phase of life during which people remain healthy and functionally capable for as long as possible.
However, the changes in individual health markers observed in the mouse model do not mean that an extended healthspan or lifespan has been proven in humans.
How should the study results be classified scientifically?
The 2011 study is a contribution to the experimental research on telomerase and its potential biological functions.
For a proper interpretation, however, several limitations must be taken into account:
- The study was conducted on mouse cells and mice.
- Animal models differ significantly from humans in terms of telomere biology in some respects.
- The observed changes in individual metrics cannot automatically be equated with a clinical health benefit.
- The results do not allow for a definitive assessment of long-term safety in humans.
- Suitable clinical studies are required for statements regarding health effects in humans.
The preclinical findings should therefore be classified as results of basic and animal research.
Further information on human studies and the clinical data situation can be found in our article TA-65®: Current studies on telomere length and safety.
Frequently asked questions about the TA-65® mouse study
Was TA-65® studied in humans in this study?
No. The publication describes preclinical experiments on mouse cells and mice. It was not a clinical study in humans.
What changes in telomeres were observed?
Under specific experimental conditions, changes in telomerase activity and a reduction in the proportion of particularly short telomeres were detected.
Did TA-65® extend the lifespan of the mice?
The study focused on various age-related health markers and telomere parameters. An extension of lifespan was not proven by this publication.
Was an increased cancer risk detected?
The authors did not report a statistically significant increase in overall cancer incidence during the animal experiments. However, no general safety can be inferred from this, especially not for humans.
Can the results be transferred to humans?
A direct transfer is not possible. Clinical investigations are required to assess potential health effects and risks in humans.
Conclusion: What does the TA-65® study in the mouse model show?
The study published in 2011 investigated TA-65® in cell culture experiments and in adult and aged mice.
The researchers observed changes in telomerase activity, certain telomere parameters, and individual age-related health markers.
These results are interesting for research into telomere biology and cellular aging mechanisms.
However, they do not provide direct evidence that TA-65® slows down the aging process, prevents specific diseases, or extends the lifespan in humans.
Original scientific publication
Bernardes de Jesus, B. et al. (2011): The telomerase activator TA-65 elongates short telomeres and increases health span of adult/old mice without increasing cancer incidence. Aging Cell, 10(4), 604–621.
